Robert Stott

On Oct. 24, 2023, Debra Houry, MD, MPH, chief medical officer and deputy director for program and science at the CDC, issued a grim warning to members of the media: Burnout among health care workers “has reached crisis levels.”“The COVID-19 pandemic only intensified many health workers’ long-standing challenges and contributed to new and worsening concerns including

LAS VEGAS — Early treatment with tumor necrosis antagonist was linked to 79% reduced odds of patients with pediatric Crohn’s disease developing perianal fistulizing complications, noted a presenter at the Crohn’s & Colitis Congress.“Perianal fistulas are very common, particularly in children with Crohn’s disease,” Jeremy Adler, MD, MSc, interim director at

The FDA has granted fast track designation to GSK's bepirovirsen, a triple action investigational antisense oligonucleotide, for the treatment of chronic hepatitis B virus infection , according to a manufacturer release.

The FDA has granted orphan drug designation to Ionis Pharmaceuticals' olezarsen, an investigational ligand-conjugated antisense drug for the treatment of familial chylomicronemia syndrome, according to a company release.

In a Healio video exclusive, Edward V. Loftus Jr., MD, urged gastroenterologists to familiarize themselves with a “four-pronged approach to liver disease” ahead of the critical shortage of U.S. hepatologists expected by 2033.

The FDA has approved Mirium Pharmaceuticals' Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

Madrigal Pharmaceutical's Rezdiffra received accelerated FDA approval for the treatment of patients with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, according to a company release.

In a Healio video exclusive, Edward V. Loftus Jr., MD, urged gastroenterologists to prioritize identifying food triggers and recommending dietary interventions and behavioral therapy for patients with irritable bowel syndrome.

In a Healio video exclusive, Edward V. Loftus Jr., MD , noted that although some concerns remain for switching patients between interchangeable

Without prompt reform of Medicare reimbursement, which has failed to keep pace with the rising operation costs of rheumatology practice, rheumatologists may have no choice but to opt out of the Medicare program, noted Christina Downey, MD.“When rheumatologists don’t participate in Medicare, it closes access to a large swath of the population,” Downey, the chair of the